RIGEL PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent of 3.20% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign · last filed 2025-03-04
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, foreign, percent for fiscal 2024 was 3.20%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent 12 month |
|---|---|
| 2024-12-31 | 3.20% 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |